Clinical Trial Update: Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 efficacy trial evaluating GlaxoSmithKline's HPV-16/18 vaccine (GSK 580299) to prevent cervical infection with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• HPV-16/18 vaccine (GSK 580299) (Human papillomavirus vaccine type 16 and 18)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 2 | Status: COMPLETED